For example, recent clinical trials of molecules inhibiting TGF-β and pirfenidone, a first in-class anti-fibrotic small molecule approved for idiopathic pulmonary fibrosis treatment, reported limited efficacy for kidney fibrosis [30]. The gene discussed is TGFB1; the disease is idiopathic pulmonary fibrosis.